RETRACTED ARTICLE: Cyr61 suppresses the growth of non-small-cell lung cancer cells via the β-catenin–c-myc–p53 pathway
Abstract
Cysteine-rich protein 61 (Cyr61) is a growth factor-inducible, immediate-early gene that has multifaceted activities in various cancers. In a previous study, we found that Cyr61 inhibited the growth of the H520 and H460 non-small-cell lung cancer (NSCLC) cell lines. In further studies, we now report that p53 plays a pivotal role in Cyr61-dependent cellular growth arrest. Blocking Cyr61 with a Cyr61 antibody resulted in the downregulation of expression of p53 and p21, as well as partially reversing the growth suppression of H520-Cyr61 cells. Proliferation of NSCLC cell lines (NCI-H157, H125, H1299), having a mutant p53, were not suppressed by Cyr61. Inhibition of wild-type p53, by either human papilloma virus type 16 E6 or a dominant-negative p53, resulted in the rescue of the growth suppression mediated by Cyr61 in the H520-Cyr61 cells. The enhanced levels of p21WAF1 and p130/RB2, in the Cyr61-expressing H520-Cyr61 cells, were also inhibited by blocking p53 showing that p21 and p130 were induced by p53 in these cells. In addition, levels of both c-myc and beta-catenin increased in Cyr61 stably transfected H520 cells. Moreover, beta-catenin was translocated into the nucleus in these cells. Inhibition of c-myc expression in the H520-Cyr61 cells with antisense c-myc resulted in their decreased levels of p53. Transfecting cells with a dominant-negative T-cell factor (TCF4), the specific inhibitor of the beta-catenin/TCF4 complex, downregulated the expression of c-myc. Taken together, the data suggest that Cyr61 suppressed the growth of NSCLC cells by triggering a signal transduction pathway through beta-catenin. In this pathway, Cyr61 activated the beta-catenin/TCF4 complex, which promoted the expression of c-myc and the latter induced expression of p53, and p53 upregulated p21WAF1 and p130/RB2, resulting in growth arrest.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CCN1 inhibits NSCLC cell proliferation by upregulating p53, p21, and p130/pRb.
“CCN1 inhibits NSCLC cell proliferation by upregulating p53, p21, and p130/pRb [158], suggesting that CCN1 may induce senescence through a p53 and pRb-dependent pathway [2].”
From CCN1/CYR61: the very model of a modern matricellular protein (2011) · cites this paper as [158]
The citation lists haven’t been fetched yet
References 70 · Cited by 86
- Authors
- Tong, X., O'Kelly, J., Xie, D., Mori, A., Lemp, N., McKenna, R., Miller, C. W., & Koeffler, H. P.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Venue
- Oncogene
- Published
- 2004-04-12
- Volume
- 23
- Issue
- 28
- Pages
- 4847-4855
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2060816138
- Cited by
- 86
- References
- 70
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 1 · 2022: 3 · 2021: 5 · 2020: 5 · 2019: 5 · 2018: 3 · 2017: 3 · 2016: 8 · 2015: 3 · 2014: 7 · 2013: 3 · 2012: 7
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Status
- Retracted
- Update notices
- retraction (2025-10-28)
- Open access
- closed
- Licence
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (CA90388, P50CA090388)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Connective Tissue Growth Factor Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- CYR61, non-small cell lung cancer, β-catenin, c-Myc, p53, p21, TCF4, growth arrest, tumor suppressor, cell proliferation, retracted article, H520 cells, H460 cells, H1299 cells
- MeSH terms
- Carcinoma, Non-Small-Cell Lung, Cell Division, Cytoskeletal Proteins, Humans, Lung Neoplasms, Models, Biological, Recombinant Proteins, Transfection, Trans-Activators, Tumor Suppressor Protein p53, Proto-Oncogene Proteins c-myc, Immediate-Early Proteins, Intercellular Signaling Peptides and Proteins, Cell Line, Tumor, beta Catenin, Cysteine-Rich Protein 61
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review